The PARP‐ATR inhibitor combination caused the complete regression of BRCA‐mutated ovarian cancer PDX tumours, while the PARP‐CHK1 inhibitor combination led only to tumour suppression rather than to tumour regression. This evidence concerns the gene CHEK1 and ovarian cancer.